BioSpace News Archive

Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.

This morning, BMS said Zeposia achieved positive topline results in the Phase III True North clinical study in patients with moderate to severe ulcerative colitis.

Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.

CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.

Pfizer has its eye on supporting innovation in the biotech industry to support small and medium-sized companies working in indications that fall under Pfizer’s core areas of focus.

When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.

U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn recently gave a speech to the Alliance for a Stronger FDA. In it, he suggested that some of the changes forced on the agency by the COVID-19 pandemic are likely to become permanent.

CE-IVD marked molecular diagnostic tests on the Novodiag® and Amplidiag® platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release

Livongo Health, Inc. (“Livongo”) (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the pricing of $475.0 million aggregate principal amount of 0.875% convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities